PTPRJ抗体;PTPRJ Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11327(PTPRJ Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The PTPRJ antibody targets the protein tyrosine phosphatase receptor type J (PTPRJ), also known as DEP-1 or CD148. PTPRJ is a transmembrane receptor-type phosphatase involved in regulating cellular signaling pathways, particularly those controlling cell growth, differentiation, and apoptosis. It acts as a tumor suppressor by dephosphorylating and inactivating key oncogenic receptor tyrosine kinases (RTKs), such as EGFR, MET, and VEGFR2. thereby modulating downstream pathways like MAPK and PI3K/AKT. Dysregulation of PTPRJ has been linked to cancers, including colon, breast, and lung tumors, where its loss or mutation can promote uncontrolled proliferation and angiogenesis.

Antibodies against PTPRJ are essential tools for studying its expression, localization, and function in both normal and pathological contexts. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to assess protein levels in tissues or cell lines. Research using these antibodies has highlighted PTPRJ's dual roles in cancer: while often tumor-suppressive, it may paradoxically support metastasis in certain microenvironments. Additionally, PTPRJ's extracellular fibronectin-III domains and intracellular catalytic domain make it a structurally complex target, requiring antibodies validated for specific epitopes. Understanding PTPRJ's mechanisms through antibody-based studies holds promise for developing therapeutic strategies targeting phosphatase-related pathways.